​
​

Purple Biotech (PPBT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PPBT Stock Forecast

Purple Biotech stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

PPBT Analyst Ratings

Buy

According to 1 Wall Street analysts, Purple Biotech's rating consensus is 'Buy'. The analyst rating breakdown for PPBT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 19, 2024H.C. WainwrightBuyBuyHold
Row per page
Go to

Purple Biotech's last stock rating was published by H.C. Wainwright on Sep 19, 2024. The company gave PPBT a "Buy" rating, the same as its previous rate.

Purple Biotech Financial Forecast

Purple Biotech Revenue Forecast

Dec 24Sep 24Jun 24
Revenue---
Avg Forecast---
High Forecast---
Low Forecast---
# Analysts---
Surprise %---

Purple Biotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PPBT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Purple Biotech EBITDA Forecast

Dec 24Sep 24Jun 24
# Analysts---
EBITDA---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

undefined analysts predict PPBT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Purple Biotech's previous annual EBITDA (undefined) of $NaN.

Purple Biotech Net Income Forecast

Dec 24Sep 24Jun 24
# Analysts---
Net Income---
Avg Forecast$-6.06M$-33.04M$-63.32M
High Forecast$-6.06M$-33.04M$-63.32M
Low Forecast$-6.06M$-33.04M$-63.32M
Surprise %---

Purple Biotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PPBT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Purple Biotech SG&A Forecast

Dec 24Sep 24Jun 24
# Analysts---
SG&A---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Purple Biotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PPBT last annual SG&A of $NaN (undefined).

Purple Biotech EPS Forecast

Dec 24Sep 24Jun 24
# Analysts---
EPS---
Avg Forecast$-0.22$-1.20$-2.30
High Forecast$-0.22$-1.20$-2.30
Low Forecast$-0.22$-1.20$-2.30
Surprise %---

According to undefined Wall Street analysts, Purple Biotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PPBT previous annual EPS of $NaN (undefined).

Purple Biotech Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BNOXBionomics$0.30$6.001900.00%Buy
ENLVEnlivex Therapeutics$1.03$15.001356.31%Buy
PMVPPMV Pharmaceuticals$1.59$18.001032.08%Buy
PPBTPurple Biotech$2.62$11.00319.85%-
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
CVKDCadrenal Therapeutics$15.13$32.00111.50%Buy
SABSSAB Biotherapeutics$3.24$5.6775.00%Buy
MNPRMonopar Therapeutics$19.01$29.5055.18%Buy
SLNOSoleno Therapeutics$51.79$76.0046.75%Buy

PPBT Forecast FAQ

Is Purple Biotech a good buy?

Yes, according to 1 Wall Street analysts, Purple Biotech (PPBT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of PPBT's total ratings.

What are Purple Biotech's analysts' financial forecasts?

PPBT's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-102M (high $-102M, low $-102M), average SG&A $0 (high $0, low $0), and average EPS is $-3.72 (high $-3.72, low $-3.72).